Toxicity studies of poly(anhydride) nanoparticles as carriers for oral drug delivery

Pharmaceutical Research

Volumn 29, Issue 9, 2012, Pages 2615-2627

  Ojer, Patricia ^a   De Cerain, Adela López ^a   Areses, Paloma ^b   Peñuelas, Ivan ^b   Irache, Juan M ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Biodistribution; Nanoparticles; Oral; Poly (anhydride); Toxicity

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; MACROGOL 6000; TECHNETIUM 99M;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMICAL STRUCTURE; CHRONIC TOXICITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; FEMALE; GASTROINTESTINAL TOXICITY; IN VIVO STUDY; INTESTINE; ISOTOPE LABELING; LD 50; MALE; MATERIAL COATING; MOUTH DISEASE; NANOANALYSIS; NANOTOXICOLOGY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; SOLVATION; TISSUE DISTRIBUTION; TOXICOKINETICS; ZETA POTENTIAL;

EID: 84866639510     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-012-0791-8     Document Type: Article

References (43)

1. Singh R, Nalwa HS. Medical applications of nanoparticles in biological imaging, cell labeling, antimicrobial agents, and anticancer nanodrugs. J Biomed Nanotechnol. 2011;7(4):489-503.
2. De Jong WH, Borm PJ. Drug delivery and nanoparticles: Applications and hazards. Int J Nanomed. 2008;3(2):133-49.
3. Lanone S, Boczkowski J. Biomedical applications and potential health risks of nanomaterials: Molecular mechanisms. Curr Mol Med. 2006;6(6):651-63.
4. Moghimi SM, Hunter AC, Murray JC. Nanomedicine: Current status and future prospects. FASEB J. 2005;19(3):311-30.
5. Vauthier C, Labarre D, Ponchel G. Design aspects of poly (alkylcyanoacrylate) nanoparticles for drug delivery. J Drug Target. 2007;15(10):641-63.
6. Chan JM, Valencia PM, Zhang L, Langer R, Farokhzad OC. Polymeric nanoparticles for drug delivery. Methods Mol Biol. 2010;624:163-75.
7. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloid Surf B: Biointerf. 2010;75(1):1-18.
8. des Rieux A, Fievez V, Garinot M, Schneider YJ, Préat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: A mechanistic approach. J Control Release. 2006;116 (1):1-27.
9. Medina C, Santos-Martinez MJ, Radomski A, Corrigan OI, Radomski MW. Nanoparticles: Pharmacological and toxicological significance. Br J Pharmacol. 2007;150(5):552-8.
10. Rivera Gil P, Oberdörster G, Elder A, Puntes V, Parak WJ. Correlating physico-chemical with toxicological properties of nanoparticles: The present and the future. ACS Nano. 2010;4 (10):5527-31.
11. Riviére G. European and international standardisation progress in the field of engineered nanoparticles. Inhal Toxicol. 2009;21 Suppl 1:2-7.
12. Clift MJD, Gehr P, Rothen-Rutishauser B. Nanotoxicology: A perspective and discussion of whether or not in vitro testing is a valid alternative. Arch Toxicol. 2011;85:723-31.
13. Organization for Economic Cooperation and Development. Nanosafety at the OECD: The First Five Years 2006-2010. Paris: OECD Publishing; 2011. Available from: Http://www.oecd.org/dataoecd/6/25/47104296.pdf.
14. Organization for Economic Cooperation and Development. Preliminary review of OECD test guidelines for their applicability to manufactured nanomaterials. Paris: OECD; 2009. Vol. No. 15 -ENV/JM/MONO (2009)21.
15. Arbós P, Campanero MA, Arangoa MA, Irache JM. Nanoparticles with specific bioadhesive properties to circumvent the pre-systemic degradation of fluorinated pyrimidines. J Control Release. 2004;96 (1):55-65.
16. Gómez S, Gamazo C, Roman BS, Ferrer M, Sanz ML, Irache JM. Gantrez AN nanoparticles as an adjuvant for oral immunotherapy with allergens. Vaccine. 2007;25(29):5263-71.
17. Agüeros M, Ruiz-Gatón L, Vauthier C, Bouchemal K, Espuelas S, Ponchel G, et al. Combined hydroxypropyl-beta-cyclodextrin and poly(anhydride) nanoparticles improve the oral permeability of paclitaxel. Eur J Pharm Sci. 2009;38(4):405-13.
18. Yoncheva K, Lizarraga E, Irache JM. Pegylated nanoparticles based on poly(methyl vinyl ether-co-maleic anhydride): Preparation and evaluation of their bioadhesive properties. Eur J Pharm Sci. 2005;24(5):411-9.
19. Yoncheva K, Guembe L, Campanero MA, Irache JM. Evaluation of bioadhesive potential and intestinal transport of pegylated poly(anhydride) nanoparticles. Int J Pharm. 2007;334(1-2):156-65.
20. Yoncheva K, CentellesMN, Irache JM. Development of bioadhesive amino-pegylated poly(anhydride) nanoparticles designed for oral DNA delivery. J Microencapsul. 2008;25(2):82-9.
21. Agüeros M, Zabaleta V, Espuelas S, Campanero MA, Irache JM. Increased oral bioavailability of paclitaxel by its encapsulation through complex formation with cyclodextrins in poly(anhydride) nanoparticles. J Control Release. 2010;145(1):2-8.
22. Calvo J, Lavandera JL, Agüeros M, Irache JM. Cyclodextrin/poly (anhydride) nanoparticles as drug carriers for the oral delivery of atovaquone. Biomed Microdevices. 2011;13(6):1015-25.
23. Ojer P, Salman H, Da Costa Martins R, Calvo J, López de Cerain A, Gamazo C, et al. Spray-drying of poly(anhydride) nanoparticles for drug/antigen delivery. J Drug Del Sci Tech. 2010;20(5):353-9.
24. Agüeros M, Campanero MA, Lrache JM. Simultaneous quantification of different cyclodextrins and Gantrez by HPLC with evaporative light scattering detection. J Pharm Biomed Anal. 2005;39 (3-4):495-502.
25. Zabaleta V, Campanero MA, Irache JM. An HPLC with evaporative light scattering detection method for the quantification of PEGs and Gantrez in PEGylated nanoparticles. J Pharm Biomed Anal. 2007;44(5):1072-8.
26. Areses P, Agüeros MT, Quincoces G, Collantes M, Richter JA, López-Sánchez LM, et al. Molecular imaging techniques to study the biodistribution of orally administered (99m)Tc-labelled naive and ligand-tagged nanoparticles. Mol Imaging Biol. 2011;13 (6):1215-23.
27. Organization for Economic Cooperation and Development. Test No. 425: Acute oral toxicity: Up-and-down procedure. Guidelines for the testing of chemicals. Paris: OECD; 2006.
28. Organization for Economic Cooperation and Development. Test No. 407: Repeated dose 28-day oral toxicity study in rodents. Guidelines for the testing of chemicals. Paris: OECD; 2001.
29. Arbós P, Wirth M, Arangoa MA, Gabor F, Irache JM. Gantrez AN as a new polymer for the preparation of ligand-nanoparticle conjugates. J Control Release. 2002;83(3):321-30.
30. Sharma NC, Galustians HJ, Qaquish J, Galustians A, Rustogi KN, PetroneME, et al. The clinical effectiveness of a dentifrice containing triclosan and a copolymer for controlling breath odor measured organoleptically twelve hours after toothbrushing. J Clin Dent. 1999;10(4):131-4.
31. Andrews GP, Jones DS. Poly(methyl vinyl ether/maleic anhydride). In: Rowe RC, Sheskey PJ, Quinn ME, editors. Handbook of pharmaceutical excipients. 6th ed. Washington DC: American Pharmacists Association; 2009. p. 534-5. London: Pharmaceutical Press.
32. Chiu GN, Wong MY, Ling LU, Shaikh IM, Tan KB, Chaudhury A, et al. Lipid-based nanoparticulate systems for the delivery of anti-cancer drug cocktails: Implications on pharmacokinetics and drug toxicities. Curr Drug Metab. 2009;10(8):861-74.
33. Kean T, Thanou M. Biodegradation, biodistribution and toxicity of chitosan. Adv Drug Deliv Rev. 2010;62(1):3-11.
34. Sonaje K, Lin YH, Juang JH, Wey SP, Chen CT, Sung HW. In vivo evaluation of safety and efficacy of self-assembled nanoparticles for oral insulin delivery. Biomaterials. 2009;30:2329-39.
35. Pokhartar V, Dhar S, Bhumkar D, Mali V, Bodhankar S, Prasad BLV. Acute and subacute toxicity studies of chitosan reduced gold nanoparticles: A novel carrier for therapeutic agents. J Biomed Nanotecnol. 2009;5:233-9.
36. Wang B, Feng WY, Wang TC, Jia G, Wang M, Shi J-W, et al. Acute toxicity of nano-and micro-scale zinc powder in healthy adult mice. Toxicol Let. 2006;161:115-23.
37. Wang J, Zhou G, Chen C, YuH, Wang T, Ma Y, et al. Acute toxicity and biodistribution of different sized titanium dioxide particles in mice after oral administration. Toxicol Lett. 2007;168:176-85.
38. Takeuchi H, Yamamoto H, Niwa T, Hino T, Kawashima Y. Enteral absorption of insulin in rats from mucoadhesive chitosancoated liposomes. Pharm Res. 1996;13:896-901.
39. das Neves J, Bahia MF, Amiji MM, Sarmento B. Mucoadhesive nanomedicines: Characterization and modulation of mucoadhesion at the nanoscale. Expert Opin Drug Deliv. 2011;8(8):1085-104.
40. Hayes AW. Principles and methods of toxicology. 4th ed. Philadelphia: Taylor & Francis; 2001.
41. Dhar S, Mali V, Bodhankar S, Shiras A, Prasad BLV, Pokharkar V. Biocompatible gellan gum-reduced gold nanoparticles: Cellular uptake and subacute oral toxicity studies. J Appl Toxicol. 2011;31:411-20.
42. Dandekar PP, Jain R, Patil S, Dhumal R, Tiwari D, Sharma S, et al. Curcumin-loaded hydrogel nanoparticles: Application in antimalarial therapy and toxicological evaluation. J Pharm Sci. 2010;99:4992-5010.
43. Kim WY, Kim J, Park JD, Ryu HY, Yu IJ. Histological study of gender differences in accumulation of silver nanoparticles in kidneys of Fischer 344 rats. J Toxicol Envirom Health A. 2009;72:1279-84.